BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ljung R, Karim FA, Saxena K, Suzuki T, Arkhammar P, Rosholm A, Giangrande P; The Pioneer™1 Investigators. 40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors. J Thromb Haemost 2013;11:1260-8. [DOI: 10.1111/jth.12237] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Mannucci PM, Peyvandi F. Introduction and overview. Blood Reviews 2015;29:S1-3. [DOI: 10.1016/s0268-960x(15)30001-1] [Reference Citation Analysis]
2 Young G, Escobar MA, Pipe SW, Cooper DL. Safety and efficacy of recombinant activated coagulation factor VII in congenital hemophilia with inhibitors in the home treatment setting: A review of clinical studies and registries. Am J Hematol 2017;92:940-5. [DOI: 10.1002/ajh.24811] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
3 Meeks SL, Leissinger CA. The evolution of factor VIIa in the treatment of bleeding in haemophilia with inhibitors. Haemophilia 2019;25:911-8. [PMID: 31489759 DOI: 10.1111/hae.13845] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
4 Lisman T, de Groot PG. The role of cell surfaces and cellular receptors in the mode of action of recombinant factor VIIa. Blood Reviews 2015;29:223-9. [DOI: 10.1016/j.blre.2014.12.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
5 Teitel JM. Treatment and prevention of bleeding in congenital hemophilia A patients with inhibitors. Transfusion and Apheresis Science 2018;57:466-71. [DOI: 10.1016/j.transci.2018.07.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Wei Q, Tian H, Zhang F, Sai W, Ge Y, Gao X, Yao W. Establishment of an HPLC-based method to identify key proteases of proteins in vitro. Anal Biochem 2019;573:1-7. [PMID: 30849379 DOI: 10.1016/j.ab.2019.02.030] [Reference Citation Analysis]
7 Behrens C, Buchardt J. Sialyltransferase-mediated glycoPEGylation. Polymer-Protein Conjugates. Elsevier; 2020. pp. 251-69. [DOI: 10.1016/b978-0-444-64081-9.00012-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Meeks SL, Batsuli G. Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches. Hematology Am Soc Hematol Educ Program 2016;2016:657-62. [PMID: 27913543 DOI: 10.1182/asheducation-2016.1.657] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 6.2] [Reference Citation Analysis]
9 Salas J, Liu T, Lu Q, Kulman JD, Ashworth T, Kistanova E, Moore N, Pierce GF, Jiang H, Peters R. Enhanced Pharmacokinetics of Factor VIIa as a Monomeric Fc Fusion. Thrombosis Research 2015;135:970-6. [DOI: 10.1016/j.thromres.2014.12.018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
10 Lentz SR, Ehrenforth S, Karim FA, Matsushita T, Weldingh KN, Windyga J, Mahlangu JN; adept™2 investigators. Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa. J Thromb Haemost 2014;12:1244-53. [PMID: 24931322 DOI: 10.1111/jth.12634] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 6.5] [Reference Citation Analysis]
11 Ragni MV. New and Emerging Agents for the Treatment of Hemophilia: Focus on Extended Half-Life Recombinant Clotting Proteins. Drugs 2015;75:1587-600. [PMID: 26310188 DOI: 10.1007/s40265-015-0451-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
12 Shibeko AM, Woodle SA, Mahmood I, Jain N, Ovanesov MV. Predicting dosing advantages of factor VIIa variants with altered tissue factor-dependent and lipid-dependent activities. J Thromb Haemost 2014;12:1302-12. [PMID: 24913469 DOI: 10.1111/jth.12628] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
13 Binder U, Skerra A. Current Strategies for Pharmacokinetic Optimization. In: Rosenberg A, Demeule B, editors. Biobetters. New York: Springer; 2015. pp. 269-311. [DOI: 10.1007/978-1-4939-2543-8_14] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
14 Mahlangu J, Paz P, Hardtke M, Aswad F, Schroeder J. TRUST trial: BAY 86‐6150 use in haemophilia with inhibitors and assessment for immunogenicity. Haemophilia 2016;22:873-9. [DOI: 10.1111/hae.12994] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
15 Morfini M, Rapisarda CAP. Safety of recombinant coagulation factors in treating hemophilia. Expert Opin Drug Saf 2019;18:75-85. [PMID: 30681006 DOI: 10.1080/14740338.2019.1574743] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
16 Jankowski W, McGill J, Lagassé HAD, Surov S, Bembridge G, Bunce C, Cloake E, Fogg MH, Jankowska KI, Khan A, Marcotrigiano J, Ovanesov MV, Sauna ZE. Mitigation of T-cell dependent immunogenicity by reengineering factor VIIa analogue. Blood Adv 2019;3:2668-78. [PMID: 31506285 DOI: 10.1182/bloodadvances.2019000338] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
17 Matino D, Makris M, Dwan K, D'Amico R, Iorio A. Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors. Cochrane Database Syst Rev 2015;:CD004449. [PMID: 26677005 DOI: 10.1002/14651858.CD004449.pub4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
18 Mannucci PM. Half-life extension technologies for haemostatic agents. Thromb Haemost 2015;113:165-76. [PMID: 25274414 DOI: 10.1160/TH14-04-0332] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
19 Mahlangu J, Levy H, Kosinova MV, Khachatryan H, Korczowski B, Makhaldiani L, Iosava G, Lee M, Del Greco F. Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety. Res Pract Thromb Haemost 2021;5:e12576. [PMID: 34430790 DOI: 10.1002/rth2.12576] [Reference Citation Analysis]
20 Shapiro AD, Mitchell IS, Nasr S. The future of bypassing agents for hemophilia with inhibitors in the era of novel agents. J Thromb Haemost 2018;16:2362-74. [DOI: 10.1111/jth.14296] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
21 Shapiro AD. A promising on-demand treatment option for bleeding events in haemophilia patients with inhibitors. Haemophilia 2017;23:810-1. [PMID: 29149550 DOI: 10.1111/hae.13345] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Chai-Adisaksopha C, Nevitt SJ, Simpson ML, Janbain M, Konkle BA. Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors. Cochrane Database Syst Rev 2017;9:CD011441. [PMID: 28944952 DOI: 10.1002/14651858.CD011441.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
23 Larsen MS, Juul RV, Kreilgaard M, Kristensen AT, Simonsson US. Impact of trial design on the estimation of drug potency and power in clinical trials of haemophilia with inhibitors. European Journal of Pharmaceutical Sciences 2018;123:531-8. [DOI: 10.1016/j.ejps.2018.07.056] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Neufeld EJ, Négrier C, Arkhammar P, el Fegoun SB, Simonsen MD, Rosholm A, Seremetis S. Safety update on the use of recombinant activated factor VII in approved indications. Blood Reviews 2015;29:S34-41. [DOI: 10.1016/s0268-960x(15)30006-0] [Cited by in Crossref: 37] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]